Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition

Oncogene

Volumn 26, Issue 38, 2007, Pages 5655-5661

  Han, E K H ^a   Leverson, J D ^a   McGonigal, T ^a   Shah, O J ^a,b   Woods, K W ^a   Hunter, T ^b   Giranda, V L ^a   Luo, Y ^a  

^a ABBOTT LABORATORIES   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

A 443654; Akt; mTOR; Phosphorylation; Rapamycin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; A 443654; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SERINE; SMALL INTERFERING RNA; TUBERIN; UNCLASSIFIED DRUG; WORTMANNIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; IMMUNOBLOTTING; INDAZOLES; INDOLES; MORPHOLINES; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SERINE; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA; RAPTORES;

EID: 34547933680     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210343     Document Type: Article

References (27)

1. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB et al. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7: 261-269.
2. Altomare DA, Testa JR. (2005). Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464.
3. Balendran A, Casamayor A, Deak M, Paterson A, Gaffney P, Currie R et al. (1999). PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol 9: 393-404.
4. Barnett SF, Bilodeau MT, Lindsley CW. (2005). The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr Top Med Chem 5: 109-125.
5. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence Jr JC, Abraham Jr RT. (1996). Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 15: 5256-5267.
6. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. (2005). The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24: 7482-7492.
7. Cheung PC, Campbell DG, Nebreda AR, Cohen P. (2003). Feedback control of the protein kinase TAK1 by SAPK2a/ p38alpha. EMBO J 22: 5793-5805.
8. Datta SR, Brunet A, Greenberg ME. (1999). Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927.
9. Davies SP, Reddy H, Caivano M, Cohen P. (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
10. Feng J, Park J, Cron P, Hess D, Hemmings BA. (2004). Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 279: 41189-41196.
11. Granville CA, Memmott RM, Gills JJ, Dennis PA. (2006). Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 12: 679-689.
12. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N et al. (1999). Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 6: 559-568.
13. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H et al. (2004). The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213-223.
14. Hay N. (2005). The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179-183.
15. Li J, DeFea K, Roth RA. (1999). Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/ phosphatidylinositol 3-kinase pathway. J Biol Chem 274: 9351-9356.
16. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R et al. (2005). Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 4: 977-986.
17. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
18. Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D et al. (2001). Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 276: 27462-27469.
19. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictorm-TOR complex. Science 307: 1098-1101.
20. Shah OJ, Wang Z, Hunter T. (2004). Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14: 1650-1656.
21. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. (2005). Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052-7058.
22. Testa JR, Tsichlis PN. (2005). AKT signaling in normal and malignant cells. Oncogene 24: 7391-7393.
23. Thompson JE, Thompson CB. (2004). Putting the Rap on Akt. J Clin Oncol 22: 4217-4226.
24. Toker A, Newton AC. (2000). Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 275: 8271-8274.
25. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M et al. (2004). Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431: 200-205.
26. Xu B, Wilsbacher JL, Collisson T, Cobb MH. (1999). The N-terminal ERK-binding site of MEK1 is required for efficient feedback phosphorylation by ERK2 in vitro and ERK activation in vivo. J Biol Chem 274: 34029-34035.
27. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N et al. (2003). Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through down-regulation of PDGFR. J Clin Invest 112: 1223-1233.